

RESEARCH

Open Access



Fecal carriage of ESBL-producing *E. coli* and genetic characterization in rural children and livestock in the Somali region, Ethiopia: a one health approach

Abdifatah Muhummed^{1,2,4*}, Ashenafi Alemu⁵, Salome Hosch^{1,2}, Yahya Osman^{1,2,4}, Rea Tschopp^{1,2,5}, Simon Yersin³, Tobias Schindler^{1,2}, Jan Hattendorf^{1,2}, Jakob Zinsstag^{1,2}, Guéladio Cissé^{1,2} and Pascale Vonaesch³

Abstract

Background The emergence and spread of Extended-Spectrum Beta-Lactamase (ESBL)-producing *Escherichia coli* pose significant challenges for treatment of infections globally. This challenge is exacerbated in sub-Saharan African countries, where the prevalence of ESBL-producing *E. coli* is high. This, combined with the lack of a strong and supportive healthcare system, leads to increased morbidity and mortality due to treatment failures. Notably, studies in Ethiopia have primarily focused on hospital settings, leaving a gap in understanding ESBL prevalence in rural communities, where human-animal proximity may facilitate microbial exchange.

Methods We conducted a community-based study in the rural Somali region of Ethiopia, simultaneously examining the fecal carriage of ESBL-producing *E. coli* in children aged 2–5 years and their livestock (cattle, camel, goat). Fecal samples from 366 children and 243 animals underwent phenotypic screening for ESBL-producing *E. coli*. Following phenotypic confirmation, ESBL resistance genes were identified via conventional PCR. Whole-genome sequencing (WGS) was performed on a subset of isolates from human feces.

Results We found that 43% (159/366) of children and 3.7% (9/244) of livestock harbored ESBL-producing *E. coli*. The ESBL gene *bla*_{CTX-M-15} was predominant in human (82.7%, 120/145) and livestock (100%) isolates. In the 48 human *E. coli* isolates subjected to WGS, a high diversity resulting in 40 sequence types (STs) was observed. Among these, ST-2353 was the most prevalent (5/48), followed by ST-10 and ST-48 (3/48) and ST-38, ST-450, and ST-4750 (2/48). These STs were associated with multiple resistance genes, such as *bla*_{CTX-M-15}, *bla*_{TEM-1B}, *bla*_{OXA-1}, *bla*_{CTX-M-14} and *bla*_{TEM-35}.

Conclusion We report a high prevalence of ESBL *E. coli* in rural children, which outnumbers its prevalence in livestock. These isolates displayed a high diversity of sequence types (STs) with ST-2353 being the dominant ST. Our study is the first to report the association of ST-2353 with multi-drug resistance genes in Ethiopia. Further research using an integrated approach including other domains such as water and food products is needed to truly understand and combat AMR transmission and acquisition in this region.

Keywords Antimicrobial resistance, Extended spectrum beta lactamase, *E. coli*, One Health

*Correspondence:

Abdifatah Muhummed
abdifatah.muhammed@swisstph.ch; AbdifatahMuktar.Muhummed@unil.ch
Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Introduction

The emergence and spread of multidrug-resistant bacterial strains, particularly Extended-Spectrum Beta-Lactamase (ESBL)-producing *Escherichia coli* (*E. coli*), pose significant challenges for treatment of infections globally [1]. These are exacerbated in sub-Saharan African countries, including Nigeria, Tanzania and Ghana, where the prevalence of ESBL-producing *E. coli* is high, both in humans (up to 60%) and animals (up to 56%) [2–6]. This, combined with the lack of a strong and supportive healthcare system, leads to increased morbidity and mortality due to treatment failures [7]. Robust laboratory diagnostics and strong surveillance systems for antimicrobial resistance are urgently needed, yet, they are still lacking in many parts of sub-Saharan Africa [8].

ESBLs are enzymes that hydrolyze a broad range of beta-lactam antibiotics, conferring resistance to multiple antibiotics [9]. CTX-M, a dominant ESBL type, has become widespread globally after the late 1990s, outpacing TEM and SHV [10]. Nowadays, its prevalence is high in infections of humans and food-producing animals, and it is considered one of the main contributing factors to multidrug resistance in *E. coli* in both low- and middle-income (LMICs) and Western countries [11–13].

ESBL genes, commonly found in plasmids, primarily spread through horizontal gene transfer [14, 15]. Recent findings suggest they can also exist in the chromosome, indicating potential clonal transmission [16, 17]. Transmission of ESBL-producing *E. coli* from animals to humans, often discussed in the context of contaminated animal-origin food, is a concern [18]. Surveillance relies on identifying similar clones, plasmids, or sequence types in human and animal populations, to infer transmission [19]. The interconnectedness of infections in both species underscores the need for a One Health approach to fully understand the dynamics and spread of resistant clones.

In Ethiopia, recent studies have revealed a high prevalence of *bla*_{CTX-M} especially the *bla*_{CTX-M-15} variant (87.7–88.4%), within hospital settings, which also conferred resistance to non-beta-lactam antibiotics, such as fluoroquinolones and aminoglycosides [20–22]. Additionally, these studies reported different *E. coli* phylogroups, with several isolates linked to the ST-131 clone, which is mainly associated with *bla*_{CTX-M-15} [20–22]. Notably, studies in Ethiopia have primarily focused on hospital settings, leaving a gap in understanding ESBL prevalence in rural communities, where human-animal proximity may facilitate microbial exchange.

To fill this gap, we conducted a community-based study to investigate the fecal carriage of ESBL-producing *E. coli* in children aged two to five years and livestock of the same households and genetically characterized the isolated clones in the feces of children and livestock. By

identifying the prevalence of ESBL-producing *E. coli* and their genetic characteristics, this study yields new insights to guide interventions aimed at curbing the dissemination of antimicrobial resistance and enhancing treatment strategies for infectious diseases caused by these bacteria.

Methods

Study area

The study was carried out from May 2021 until June 2021 in Adadle district in the Shebele zone, Somali Regional State (SRS), Ethiopia.

Sample size

Based on a previous study conducted in Addis Ababa, we expected the prevalence of ESBL-producing *E. coli* to be 42% [23] and assumed an inter-cluster correlation coefficient of 0.15. We calculated a sample size of 360 eligible children, with 180 children from pastoralist and 180 children from agro-pastoralist communities to be sufficient to estimate the prevalence with a margin of error of 10% at the 95% confidence level.

Selection criteria

Based on the nature of livelihood, eight of the thirteen Kebele in the Adadle district were randomly selected. Among the selected Kebele, four were pastoralist (Malkasalah, Todab, Harsug, Boholhagere) and four were agro-pastoralist (Bursaredo, Dabafyd, Gabal, Higlo).

A pre-enrolment screening was carried out in each Kebele to assess children between 2 and 5 years of age. All children were screened for stunting and wasting based on WHO guidelines. All stunted (height for age score, HAZ < -2), and wasted (weight for height score, WHZ < -2 or mid-upper arm circumference (MUAC) < 11.5 cm) were enrolled in the study. Among the screened children who were non-stunted and/or non-wasted, a random selection process was employed from an Excel file containing information on all pre-screened households/children in the community. The random selection process continued until the desired sample size was achieved. Children outside the age range (below 2 years and above 5 years) and those who had received antibiotic treatment within the last 14 days were excluded from the study. Informed consent was obtained from all participants' legal guardians.

Anthropometric measurements

Height measurements were taken with children standing against a WHO standard wooden measuring board, ensuring the correct posture and position. Weights were recorded using a WHO standard weight scale, either the child alone or with the mother by adjusting

the weight scale [24]. MUAC measurements were performed using a WHO standard tape measure. To ensure the accuracy of height, weight and MUAC measurements, each anthropometric measurement was repeated at least twice or until the measurements were within 1 mm, 100 g, or 1 mm of one another, respectively.

Data collection

A comprehensive questionnaire was administered to the mother of the child by trained field workers in the local language using Open Data Kit (ODK). The questionnaire covered different sections, including demographic characteristics, child health status, WASH behavior, breastfeeding, diet, and anthropometric measurements. As birth records were not available in the community, the child's age was estimated based on group discussion involving the child's mother, as well as other family and community members. These discussions considered factors such as seasonal events (floods, drought, and rainy season) and festive occasions (Ramadan, festival, and other religious events) that occurred before and after the child's birth. Additionally, leveraging the close-knit relationships within the community, efforts were made to engage in discussions to collectively recollect and remind each other about significant events and timeframes related to the child's birth.

Stool sample collection

Trained field workers provided mothers with instructions in the local language a day before collecting fecal samples. Mothers used sterile specimen cups, and upon receipt, samples were placed in an ice box and transported within 2–4 h to a field laboratory. There, samples were aliquoted into six cryotubes, two with glycerol (40% glycerol mixed 1:1 with the stool) and four without, stored at 4 °C. Subsequently, samples were sent to Gode within 24 h, stored at –20 °C, and then shipped to the Armauer Hansen Research Institute in Addis Ababa, where they were preserved at –80 °C for long-term storage.

Additionally, from the selected households that owned animals, we assessed different types of animals (camels, cattle, and goats). We randomly sampled at least one animal per species. Animal fecal samples were collected by a veterinary professional through either rectal insertion of gloved hands or aseptic collection of fresh stool (if the animals defecated in the presence of the team). Animal samples underwent a process similar to human samples—immediate shipment to the field laboratory, aliquoting, storage at –20 °C, and final storage in Addis Ababa at –80 °C for future analysis.

Bacterial isolation and identification

Fecal samples were aseptically inoculated onto MacConkey agar plates (Oxoid, UK) [25], and subsequently, a cefotaxime disc was placed at the center of the plate. The plates were then incubated for 24 h at 37 °C. The *E. coli* colony closest to the cefotaxime disc was meticulously selected based on its distinctive morphology and pigmentation characteristics. The selected colonies were re-inoculated overnight to ensure purity and, and subsequently, the colony was confirmed as *E. coli* through a biochemical test. Isolates were classified as *E. coli* if they exhibited a positive indole test, negative citrate, positive lysine decarboxylation, gas and acid production, mannitol fermentation, negative urea hydrolysis, and if they were motile.

Antibiotic susceptibility test

The disc diffusion method, was used to determine the antibiotic susceptibility using Müller-Hinton agar (Oxoid, UK) according to the recommendation of the Clinical and Laboratory Standard Institute (CLSI) guidelines [26]. Antibiotic susceptibility tests were performed for 19 antibiotics from 10 different classes, including penicillins (ampicillin (AMP) 10 µg and amoxicillin (AML) 10 µg), beta-lactamase inhibitor combinations (ampicillin-sulbactam (SAM) 30 µg and amoxicillin/clavulanic acid (AMC) 30 µg), cephalosporin (cefazolin (KZ) 30 µg, cefpodoxime (CPD) 10 µg, cefuroxime (CXM) 30 µg, ceftriaxone (CRO) 30 µg, cefotaxime (CTX) 30 µg, cefipime (FEP) 30 µg, ceftazidime (CAZ) 30 µg), carbapenem (imipenem (IPM) 10 µg and ertapenem (ETP) 10 µg), monobactams (aztreonam (ATM) 30 µg), fluoroquinolones (ciprofloxacin (CIP) 5 µg), aminoglycosides (gentamicin (CN) 30 µg), macrolides (azithromycin (AZM) 15 µg), tetracycline (TE) 30 µg), and cotrimoxazole (SXT) 25 µg (Oxoid, United Kingdom). McFarland standard 0.5 was used prior to spreading the suspension on the Müller-Hinton agar plate to ensure the bacterial suspension turbidity. Plates were incubated at 37 °C for 18 h. Based on the inhibition zone diameters, antibiotics were assigned to susceptible, intermediate, and resistant as indicated by CLSI guidelines [26]. Multidrug resistance was defined as non-susceptible to at least one antibiotic agent in three or more antimicrobial classes [27]. Extensive drug resistance (XDR) was defined as resistance to at least one agent in all but susceptible to two or fewer antimicrobial categories. Pan drug resistance (PDR) was defined as resistance to all agents in all antimicrobial categories [28].

ESBL screening and confirmatory test

According to CLSI guidelines, any strain showing resistance against cefotaxime 30 µg, ceftazidime 30 µg, or

ceftriaxone 30 µg was considered as a potential ESBL producer. Confirmatory tests were performed utilizing a disc of cefotaxime 30 µg and one of ceftazidime 30 µg alone, and a disc of cefotaxime and one of ceftazidime combined with clavulanic acid 10 µg (Oxoid, United Kingdom). Isolated strains were considered ESBL-producers if an increase of inhibition zone diameter of 5 mm or greater was observed in the discs of cefotaxime or ceftazidime combined with clavulanic acid compared to the inhibition observed in the cefotaxime or ceftazidime discs without clavulanic acid. *E. coli* ATCC 25922 and *E. coli* ATCC BAA-2326 were used as negative and positive controls, respectively [29].

Molecular testing for β-lactamase genes (*bla*_{CTX-M}, *bla*_{TEM} and *bla*_{SHV})

The DNA of the confirmed ESBL-producing isolates was extracted using the Wizard[®] HMW DNA Extraction Kit, according to the manufacturer's instructions [30]. The presence of three ESBL genes (*bla*_{CTX-M}, *bla*_{TEM}, and *bla*_{SHV}) was detected using a multiplex PCR approach within a single reaction tube. Details regarding the PCR reaction, cycling, and primers for amplifying the ESBL resistance genes can be found in supplementary materials 1.

Whole genome sequencing

The extracted DNA from human and animal ESBL-producing isolates were shipped to the Swiss Tropical and Public Health Institute (Swiss TPH) for whole genome sequencing (WGS). However, the DNA quality of the sub-isolates, selected based on their phenotypic profiles, was insufficient for WGS. Since we did not have the original isolates in Switzerland, we decided to re-culture and perform DNA extraction on the original fecal samples that were initially shipped with the DNA. Subsequently, 48 of these samples were selected based on the phenotypic profiles obtained in Ethiopia and the phenotypic analysis was repeated for the new isolates for the data provided in Fig. 4.

DNA concentration was quantified with the Qubit dsDNA HS Assay Kit (Invitrogen, Germany). Isolates were selected for WGS using the MinION platform (Oxford Nanopore Technologies, UK) based on DNA concentrations (>33 ng/µL). The sequencing library was prepared according to the manufacturer's instructions using the Native Barcoding Kit 96 (SQK-LSK114.96) and loaded onto the R10.4.1 flow cell and sequenced on the MinION Mk1C using super-accurate base calling.

Bioinformatics analysis

De novo assembly was conducted using Flye 2.9.1 at the scientific computing core facility of the University

of Basel [31]. The Bacterial and Viral Bioinformatics Resource Center (BV-BRC) was used for annotation and phylogenetic analysis of the assemblies. The assemblies were annotated using the RAST 2.0 toolkit [32]. Only assemblies with less than 20 contigs were considered for further analysis. Sequence type of assembled contigs were determined using MLST [33]. Phylogenetic trees were generated by aligning protein and nucleotide sequences using MUSCLE, MAFFT and RAxML [33–35]. Resistome analysis was performed using CARD (v. 6.0.0) and ResFinder (v. 4.2.2) [34, 36]. VirulenceFinder v.2.0 and PlasmidFinder v.2.1 tools available at the Center for Genomic Epidemiology were used for the virulent detection and plasmid replicon typing [37].

Statistical analysis

R statistical software v. 4.1.3 was used to perform the statistical analysis [38]. Initial descriptive analysis of variables was performed using the gtsummary package. Multivariate analysis employed logistic regression to assess the association between ESBL-producing *E. coli* and independent variables. The initial model included variables (age, sex, education, sanitation practice, hygiene, source of water, owning livestock, nutritional status) based on literature knowledge, with stepwise removal of those contributing insufficient information ($p > 0.2$). Variables with $p < 0.2$ were retained. Model fitness was assessed using likelihood ratio test, AIC (Akaike Information Criterion), and adjusted R square. Significance was determined at $p < 0.05$. R packages ape, ggplot2, ggtree, and ggtreeExtra were used for analyzing resistance genes and visualizing phylogenetic trees.

Results

Description of study population

Out of the 366 children, only 346 children completed the questionnaire and were included in this study for further analysis. Pastoralists and agro-pastoralists were evenly represented in terms of age and sex among the enrolled children. Over half of the children showed a normal growth (61%), while a quarter (25%) of them were wasted, and 7.8% were stunted. Further, 5.2% of the children suffered concomitantly from stunting and wasting. Characteristics of the study group are summarized in Table 1.

As summarized in the supplementary Table S1, the two main sources of water for pastoralists and agro-pastoralists were rainwater/birkad (89%) and river water (95%), respectively. Most of pastoralist and agro-pastoralist (96%) used open space for defecation. The 14 households (4%) that had a toilet shared it with 28 households. Dumping waste in the street or open spaces within the compound was the predominant method of waste disposal in both pastoralist and

Table 1 Characteristic of pastoralist and agro-pastoralist in the Adadle district, Somali region, Ethiopia

Variables	N = 346 (%)
Settlement area	
Pastoralist	177 (51.2%)
Agro-Pastoralist	169 (48.8%)
Education of the mothers	
Formal education	50 (14.5%)
Non-formal education	36 (10.4%)
Illiterate	260 (75.1%)
Sex of the child	
Female	176 (50.9%)
Male	170 (49.1%)
Age group of the child	
2 years	150 (43.4%)
3 years	98 (28.3%)
4–5 years	98 (28.3%)
Number of children per household	
1–3 children	78 (22.5%)
4–6 children	160 (46.2%)
> = 7 children	108 (31.2%)
Completed all required vaccinations	
No	309 (89.3%)
Yes	37 (10.7%)
Has a vaccination card	
No	328 (94.8%)
Yes	18 (5.2%)
Nutritional status	
Normal growth	212 (61.3%)
Wasted	88 (25.4%)
Stunted	27 (7.8%)
Stunted and wasted	18 (5.2%)
Overweight	1 (0.3%)

agro-pastoralist societies (84%), while 16% opted to burn waste. Most mothers reported that they used water to wash the children's hands (93%), while a small subfraction of mothers reported (4%) using water and soap. At the time of the sampling, more than half of the agro-pastoralists and pastoralists had soap, while 29% did not have soap very often and 13% never had soap in their house.

Nearly half of agro-pastoralist households (43%) and 12% of pastoralist households treated the water prior to consumption (mainly chlorination (98.9%)). The majority of agro-pastoralists possessed cattle (94.7%), donkeys (81.1%), goats (62.7%), sheep (53.3%), camels (10%) and chickens (10%). Among pastoralists, predominant livestock ownership included goats (87.6%), donkeys (58.8%), sheep (44.1%), camels (36.2%), and cattle (29.9%).

Phenotypic test results for ESBL *E. coli* carriage

A total of 609 fecal samples, comprising 366 from humans and 243 from animals (including 77 goats, 136 cows, and 30 camels) were analysed. For human isolates, 159 (43%) of the *E. coli* isolates were ESBL-producers (24.5% in pastoralists and 18.8% in agropastoralists). Furthermore, 7.8% of the *E. coli* isolates from goats (6/77) and 2.2% from cows (3/136) were ESBL-producers. Regarding animal ESBL-producing isolates, 7 (77.8%) were identified among animals of agro-pastoralists, while 2 (22.2%) were found among those of pastoralists.

Susceptibility pattern for ESBL-producing *E. coli*

For the human isolates, ESBL-producing *E. coli* strains exhibited complete resistance to several commonly used antibiotics including amoxicillin, cefotaxime, cefuroxime, ceftriaxone, ceftazidime, and ciprofloxacin. Almost all ESBL-producing *E. coli* isolates (98.7%) were resistant to ampicillin and 51.6% were resistant to tetracycline.

Regarding co-trimoxazole, 57.9% of the isolates were classified as resistant, 2.5% as intermediate, and 37.7% as susceptible. Among ESBL-producing *E. coli*, 47.8%, 42.1%, and 27.7% were non-susceptible, and 32.1%, 54.7%, and 25.2% were intermediate to aztreonam, cefipime, and ceftazidime, respectively. In addition, 15.7% and 12.6% of the isolates were resistant to azithromycin and ciprofloxacin. Ampicillin-sulbactam (8.8%), gentamicin (6.9%), and amoxicillin-clavulanic acid (5.9%) had the lowest rates of resistance. Intermediate susceptibility was observed in 16.5% for amoxicillin-clavulanic acid, 15.1% for ampicillin-sulbactam, and 2.5% for gentamicin. All carbapenems (imipenem and ertapenem), which are considered the last-resort antibiotics for infections caused by ESBL-producing *E. coli*, were found to be effective against the ESBL-producing *E. coli* isolates, except for 1.3% of the isolates that had intermediate susceptibility to ertapenem. Additionally, using whole genome sequencing (WGS), none known carbapenem or colistin resistance genes were found in the *E. coli* isolates.

Additionally, nine ESBL isolates obtained from animal fecal samples exhibited complete (100%) resistance to ampicillin, cefotaxime, and amoxicillin. Furthermore, an 88.9% resistance rate was observed for cefepime, followed by ceftazidime (55.6%), ceftriaxone (44.4%), cefuroxime (44.4%), and aztreonam and ampicillin-sulbactam, which both exhibited an equal resistance rate of 33.3%. In ESBL-producing *E. coli* isolates from animals, ampicillin-clavulanic acid, ceftazidime, gentamicin, and ciprofloxacin all exhibit an equal resistance rate of 11.1%. The data is summarized in Fig. 1.

All ESBL-producing *E. coli* strains exhibited multi-drug resistance (MDR), rendering them non-susceptible to




Fig. 1 Antimicrobial resistance pattern of ESBL-producing *E. coli* isolated from the feces of children aged 2–5 years (A, 159/366) and from livestock (B, 9/243) in the Adadle district, Somali region, Ethiopia. Antimicrobial agents tested include: AMX (Amoxicillin), AMC (Amoxicillin-clavulanic acid), AMP (Ampicillin), ATM (Aztreonam), AZT (Azithromycin), CAZ (Ceftazidime), CIP (Ciprofloxacin), CN (Gentamicin), CPD (Cefpodoxime), CRO (Ceftriaxone), CTX (Cefotaxime), CCT (Cefotetan), ETP (Ertapenem), FEP (Cefepime), FOX (Cefoxitin), IMP (Imipenem), KZ (Cefazolin), SAM (Ampicillin-sulbactam), SXT (Co-trimoxazole), PIR (Piperacillin), TET (Tetracycline)

three or more antibiotic drug classes (Figure S1 in Supplementary File 1).

Thus, ESBL-carriage is very prevalent, especially in children, in a community setting and is much lower in the feces of livestock animals.

Predictors of ESBL-producing *E. coli* carriage

In the multivariable analysis, education was significantly associated with ESBL-producing *E. coli*. Children whose mothers or household heads were illiterate had twice the odds of carrying ESBL-producing *E. coli* compared to children whose mothers were formally educated (aOR=2.65, 95% CI=1.27–5.48). The odds of children who were both stunted and wasted were three times higher to harbor ESBL-producing *E. coli* compared to children with normal growth (aOR=3.14, 95%CI=1.02–9.07). Moreover, pastoralist children had 2.65 times higher odds of being colonized with ESBL producing *E. coli* compared to agro-pastoralist children (aOR=2.65, 95% CI=1.30–5.41). Counterintuitively, children who drank water treated with chlorine showed a positive association with ESBL-producing *E. coli* (aOR=2.09, 95% CI=1.10–3.98). Additionally, the possession of chicken increased the odds of infection with ESBL-producing *E. coli* five times (aOR=5.13, 95% CI=1.66–15.68). The sex and age of the child were not found to be significantly associated with infection with ESBL-producing *E. coli*. Similarly, although owing soap or washing hands with

water and soap showed a trend to decrease the risk of contracting ESBL-producing *E. coli*, this association was not statistically significant (Fig. 2).

Genetic characterization of ESBL strains (conventional PCR)

During PCR screening, we found that the *bla*_{CTX-M-15} gene was the most prevalent resistance gene in both human (82.8%) and animal (100%) isolates. The prevalence of the *bla*_{CTX-M-15} resistance gene was similar in isolates from the feces of pastoralists and agro-pastoralists, both almost at 80% (Figure S2 of the Supplementary Materials 1). Comparing the nine isolates from animals alongside those from children residing in the same household, we observed that only two households within the pastoralist group demonstrated simultaneous presence of *bla*_{CTX-M-15} in both their children and livestock (Figure S3).

Multi locus sequence types (MLST), phylogenetic groups and plasmid MLST

The 48 human *E. coli* isolate subjected to WGS analysis, were chosen based on their phenotypic profile. A sequence type (ST) by MLST using the Achtman scheme could be assigned to 44 isolates (91.7%), with five isolates having a single nucleotide polymorphism (SNP) in one gene (2 in *adk*, 2 in *fumC*, 1 in *mdh*). The most common ST was ST-2353 with five *E. coli* isolates, followed by ST-10 and ST-48 with three *E. coli* isolates




Fig. 2 Risk factors (multivariable model) associated with fecal carriage of ESBL-producing *E. coli* among children living in the Adadle district, Somali region, Ethiopia

each and ST-38, ST-450 and ST-4750 with two *E. coli* isolates each. All other 27 *E. coli* isolates had singular ST. A total of nine *E. coli* isolates were assigned to clonal complex ST10 (3 ST-10, 3 ST-48, 1 ST-227, 1 ST-378 and 1 ST-617) and two isolates to clonal complex ST38 (2 ST-38).

The predominant beta-lactam resistance gene among the 48 *E. coli* isolates was *bla*_{CTX-M-15}, identified in 72.9% (35/48) of the whole-genome sequenced isolates, followed by *bla*_{TEM-1B} identified in 47.9% (23/48), ampC beta-lactamase in 14.6% (7/48), *bla*_{OXA-1} in 8.3% (4/48) and *bla*_{CTX-M-55} in 4.2% of the isolates. The beta-lactam resistance genes *bla*_{CTX-M-14} and *bla*_{TEM-35} were the least prevalent, each detected in a single isolate.

Four *E. coli* isolates (8.3%) did not carry any known beta-lactam resistance genes, 20 *E. coli* isolates (41.7%) carried one, 19 *E. coli* isolates (39.6%) carried two and five *E. coli* isolates (10.4%) carried three beta-lactam resistance genes. Seventy-five percent (15/20) of *E. coli* isolates with one beta-lactam resistance gene carried only *bla*_{CTX-M-15}, while 68.4% of *E. coli* isolates with two beta-lactam resistance genes carried both *bla*_{CTX-M-15} and *bla*_{TEM-1B}.

Quinolone resistance conferred by mutations in the *gyrA* gene was detected in 33.3% (16/48) of *E. coli* isolates. Serine at position 83 was mutated to either Leucine (S83L, 10/16), Alanine (S83A, 3/16) or Valine (S83V, 3/16). In addition to S83L, three *E. coli* isolates had *gyrA*

mutation D87N. Four *E. coli* isolates (8.3%) had *parC* mutation S57T and four *E. coli* isolates (8.3%) had *parC* mutation S80I combined with *parE* mutation S458A. The plasmid-encoded *qnrS1* and *qnrS13* genes were detected in 39.6% (19/48) and 2.1% (1/48) of the sequenced isolates, respectively.

Aminoglycoside resistance genes were present in 60.4% (29/48) of *E. coli* isolates. Four different aminoglycoside (3'') (9) adenylyltransferase (*aadA*) genes were detected in 15 *E. coli* isolates (31.3%), with *aadA1* accounting for 66.7% (10/15), *aadA2* and *aadA24* for 13.3% (2/15) each and *aadA5* for 6.7% (1/15) of the *aadA* genes found. Eighteen *E. coli* isolates (39.5%) had the plasmid-encoded *aph(3'')-Ib* and *aph(6)-Id* aminoglycoside resistance genes, one had only *aph(3'')-Ib* and one only *aph(6)-Id*. The aminoglycoside resistance genes *aac(3)-IIId*, *aac(6')-Ib-cr*, *ant(2'')-Ia* and *aph(3')-Ia* were detected in one *E. coli* isolate each.

Sulfonamide resistance genes were detected in 62.5% of *E. coli* isolates (30/48), with *sul1* in 30.0% (9/30), *sul2* in 63.3% (19/30) and both genes in 6.7% (2/30) of the isolates. Trimethoprim resistance genes *dfrA* were detected in 58.3% of *E. coli* isolates (28/48), most commonly *dfrA14* (9), followed by *dfrA1* (7), *dfrA5* (3), *dfrA17* (3), *dfrA7* (2), *dfrA15* (2), *dfrA8* (1) and *dfrA19* (1). Tetracycline resistance genes *tetA*, *tetB* and *tetD* were detected in 35.4% (17/48), 16.7% (8/48) and 2.1% (1/48) of *E. coli* isolates, respectively. Macrolide resistance gene *mphA* was detected in 18.8% (9/48) of the isolates, with one isolate simultaneously carrying *ermB*. The results are summarized in figure S4.

Virulence genes and plasmids

A total of five different virulent genes were found in 15/48 of *E. coli* isolates, but none of the isolates were found to harbor Shiga-toxin genes in their genomes. The results revealed the presence of Enteroaggregative *E. coli* genes such as *aggR* (5/48), *aggA* (2/48) and *aaiC* (2/48). Additionally, both the heat-labile (*elt*) and heat-stable enterotoxigenic *E. coli* genes (*est*) were found in 7/48 and 8/48 *E. coli* isolates (Table S2).

The detection rate of IncFIB plasmid exhibited the highest frequency, found in 28/48 isolates, followed by IncFII (26/48), IncY (10/48), IncFIA (7/48) and Inc11 (6/48). Combinations of multiple plasmids were observed, with IncFIB and IncFII being the most prevalent combination, present in 17/48 isolates. Specifically, 12 isolates carrying *bla_{CTX-M-15}* resistance genes encoded both IncFIB and IncFII plasmids. Three isolates carried a combination of three plasmids (IncFIB, IncFII, IncFIA), and single isolates carried four different plasmids (IncFIB, IncFII, IncFIA, IncY) (Fig. 3).

Comparison of genotypes and phenotypes

Resistance to different antibiotics was inferred from WGS data. The presence of specific genes (Fig. 4, in blue) indicated resistance to specific antibiotics (Fig. 4, in red). For example, the presence of at least one of the following genes, CTX-M-type, OXA-type, TEM-type, or *ampC*, indicated resistance to amoxicillin, ampicillin, aztreonam, cefotaxime, ceftriaxone, cefazolin, cefuroxime, and cefepodoxime. The same procedure was used for all other antibiotics, as indicated in Fig. 4.

The resistance results inferred from WGS data were then compared with the results of the phenotypic assay. We found high concordance rate (>90%) between genotype and phenotype for azithromycin (93%), amoxicillin (91%), and ampicillin (91%). Conversely, chloramphenicol (87%), as well as several cephalosporins including cefotaxime, ceftriaxone, cefazolin, cefuroxime, and cefepodoxime, each showed a low concordance rate of 84%. Tetracycline (81%) and trimethoprim/sulfamethoxazole (72%) showed even lower concordance rates, with ciprofloxacin (63%) registering the lowest concordance rate among them. These discordances should be analysed in more detail by assessing more antibiotics and by mining for eventual new resistance mechanisms that could be encoded in these bacterial strains. The results are summarized in Fig. 4.

Discussion

Over the past two decades, there has been a significant increase in the global prevalence of communities carrying ESBL-producing *E. coli* [39]. In LMICs, the colonization of ESBL-producing *E. coli* has risen steadily in both community and healthcare settings, with the community carriage rate approaching that of healthcare settings [40]. To our knowledge, this is the first study to employ WGS for profiling of the phylogenomic of ESBL-producing *E. coli* in children under the age of five in rural communities in Ethiopia.

The results show a high carriage (43%) of ESBL-producing *E. coli* in children under the age of five living in these communities via phenotypic analysis. This finding aligns with a study conducted among hospitalized children in Addis Ababa [23] and rural children in Ghana [41]. The elevated prevalence observed could be attributed to the widespread availability of antimicrobials and misuse of antibiotics [42]. Additionally, in rural communities, limited access to clean water and sanitation may contribute the spread of ESBL-producing *E. coli* resistant clones and genes [43]. On the other hand, low prevalence of ESBL-producing *E. coli* carriage was found in livestock, which aligns with a study performed in Kenya [44]. In rural communities, limited access to veterinary care may result




Fig. 3 Plasmid replicon profiles for 48 ESBL-producing *E. coli* isolated from 2 to 5 year old children in the Adadle district, Somali Region, Ethiopia. The presence of plasmid is shown in dark gray and absence in light gray

in reduced antibiotic usage in livestock, thereby decreasing the selection pressure for antibiotic-resistant bacteria [45]. This situation could, in turn, contribute to the lower prevalence of ESBL-producing *E. coli* strains in the livestock population.

In the PCR analysis, the resistance gene *bla*_{CTX-M-15} emerged as the most frequently observed gene among *E. coli* isolates that exhibited an ESBL phenotype in our study, both in the children (120/159 isolates) and in livestock (9/9 isolates). Importantly, *bla*_{CTX-M-15} is known as the primary ESBL resistance gene responsible for human infections worldwide [46]. Moreover, recent research conducted in Africa corroborates this finding, highlighting *bla*_{CTX-M-15} as the dominant ESBL-producing *E. coli* gene in livestock populations [47]. This geographical

distribution strongly suggests a significant spread of resistance genes among both humans, animals and other domains such as water and food products, highlighting the importance of understanding and addressing this issue from a One Health perspective.

Studies in Ethiopia and Ghana also demonstrated a substantial diversity of STs, accounting for over 30 of them [2, 20]. Here, ST10 and ST48 exhibited multi-drug resistance genes, primarily *bla*_{CTX-M-15} and *bla*_{TEM-1B'} along with other non-beta-lactamase resistance genes. Globally, ST10 and ST48 are recognized as clonal genetic entities known to harbor multi-drug resistance genes, primarily in humans, with a notable prevalence of *bla*_{CTX-M-15} [48, 49]. Additionally, ST38 showed a lineage associated with the carriage of *bla*_{CTX-M-14} and *bla*_{CTX-M-15'}




Fig. 4 Concordance and discordance between genotype and phenotype for selected ESBL-producing *E. coli* isolates from Adadle district, Somali region, Ethiopia

which is consistent with prior research findings in Tanzania [50, 51].

Notably, ST2353, typically associated with highly pathogenic diarrheagenic *E. coli* strains [52, 53] and historically less reported for its resistance gene carriage, emerged as one of the predominant sequence types in our study. Remarkably, ST2353 was found to harbor multiple resistance genes, encompassing *bla*_{CTX-M-15}, *bla*_{TEM-1b}, *gyrA*, and *tetA*. This observation

underscores the potential for gene evolution over time, signifying the spread of resistance mechanisms across diverse clonal sequence types. This gene can impact the efficacy of antibiotics treatment on a population level. Hence, our findings underscore the imperative need for further comprehensive investigations aimed at elucidating the mechanisms underlying genetic mutations and the emergence of allelic variants associated with antibiotic resistance.

The IncFII-FIA-FIB multi-replicon plasmids have been commonly associated with *bla*_{CTX-M-15} resistance genes globally [54]. This was also found in our study along with other studies in Ethiopia, Tanzania, and Ghana [21, 55, 56]. These plasmids can maintain and transfer resistance genes among enterobacterial species independent of antibiotic exposure, which contributes to the dissemination of AMR genes within the community [57]. Therefore, genomic surveillance is essential to tracking the evolution of resistance determinants and assessing the effectiveness of interventions aimed at controlling AMR spread in different ecological settings.

We report a high concordance rate (>90%) between genotypic and phenotypic resistance for certain antibiotics, as similarly reported by others [58, 59]. However, lower concordance rates (<90%) were observed for certain antibiotic classes, with fluoroquinolones showing the lowest agreement. Most cases were so-called “major errors”, i.e. genotypic resistance was observed but phenotypic susceptibility was not [60]. This phenomenon may be attributed to the suppression of gene expression through transcriptional regulation, other gene silencing mechanisms or compensatory mutations [61, 62]. Similar results were noted in other studies conducted in Singapore and France [59, 61]. Further research is needed to fully explain this phenomenon.

In the multivariable analysis, we found that children whose mother were illiterate had higher odds of carrying ESBL-producing *E. coli* [63]. Furthermore, age and sex of the child were not significantly associated with ESBL-producing *E. coli* carriage. These results are consistent with prior studies conducted in Ethiopia, Guinea-Bissau, and Madagascar [63–65]. The observed link between maternal illiteracy and ESBL-producing *E. coli* colonization suggests the importance of community education in implementing effective strategies to combat this public health concern.

Children who were both stunted and wasted were significantly more likely to be colonized by ESBL-producing *E. coli*, with a three times higher odds compared with those without malnutrition [66–68]. This finding can be explained by the fact that malnutrition weakens the immunity system, making children more susceptible to infections, and more likely to be treated with antibiotics [69]. This connection may also involve the influence of microbiota and the creation of niches for colonization. Given the well-established link between antibiotic use and the emergence and spread of AMR, addressing malnutrition through public health interventions could contribute to the reduction of infections and colonization by AMR carrying bacteria.

Furthermore, the study revealed that there was a significant correlation between ESBL carriage and settlement

type, water treatment, and chicken ownership. Pastoralists were found to have higher odds of ESBL-producing *E. coli* colonization compared to agro-pastoralists. The nomadic nature of pastoralists, involving frequent travels in search of water and food, may foster shared water sources and inadequate sanitation and hygiene practices. Consequently, this situation could escalate the risk of waterborne diseases like diarrhea and facilitate the transmission of ESBL-producing *E. coli* [70]. As infectious diseases become more prevalent in such contexts, there is an associated rise in antibiotic usage, a well-established precursor to AMR [71].

Despite chlorine being the most commonly used method for water treatment in LMICs [72], this study found a positive association between children who consumed chlorine-treated water and ESBL-producing *E. coli*. This finding aligns with a randomized control trial conducted in Bangladesh, which revealed that water chlorination did not significantly decrease the fecal carriage of ESBL-producing *E. coli* in children [73]. Other studies conducted in China and South Africa also demonstrated the tolerance of chlorine in relation to AMR [74, 75]. Furthermore, a study conducted in China highlighted that chlorination promotes horizontal gene transfer through natural transformation, thus facilitating the spread and emergence of AMR [76]. Therefore, we hypothesize that the widespread use of chlorine in LMICs for water treatment may not be as effective as previously thought in reducing the prevalence and transmission of antimicrobial-resistant *E. coli* strains.

In this study, possessing chickens showed a significant relationship with ESBL-producing *E. coli*, with the odds of colonization being five times higher. Previous studies conducted in Ethiopia, Kenya, Nigeria, Ghana, Pakistan, and the Netherlands have suggested that chickens are the primary source of ESBL-producing *E. coli* transmission to humans [2, 77–82]. This suggests that there is a need of effective measures to control the spread of antimicrobial resistance in animal husbandry, with a focus on poultry as the main carriers.

We attempted to collect fecal samples from children and livestock within the same households to investigate the circulation of resistance genes between the two populations. However, due to the absence of necessary kits and machines for whole genome sequencing (WGS), we were constrained to ship the DNA to Switzerland to carry out the WGS. Since the shipment was costly, we were only able to send the DNA from human and animal fecal samples, as well as the original human fecal samples.

After running a set of DNA isolates from both human and animal samples on Nanopore, we discovered that the DNA was fragmented. Fortunately, because the human fecal samples had been shipped, we were able to

re-isolate and re-extract the DNA, and successfully perform WGS. However, since we did not have the animal fecal samples in Switzerland, we were unable to conduct WGS on these samples. This limitation restricted our ability to explore the genetic aspects of resistance gene transmission between human and animal populations comprehensively. Additionally, the limited sequencing data derived from human fecal isolates, along with the absence of sequenced data from animal fecal isolates and other One Health domains, has narrowed our focus and restricted our ability to conduct comprehensive analysis of mobile genetic elements, such as phages and insertion sequence, which is essential for the dissemination of an antimicrobial resistance. Instead of, we anticipate addressing this limitation in future projects by including a broader range of samples. This will enable a more comprehensive analysis and will contribute to the understanding of transmission and dissemination of AMR in different domains of One Health.

Conclusion

Our study represents the first study of molecular epidemiology of ESBL-producing *E. coli* isolated from rural children and livestock in Ethiopia. We found high and low prevalence of ESBL-producing *E. coli* in rural children and livestock, respectively, largely mediated by the gene *bla*_{CTX-M-15} encoded on a plasmid. The isolates displayed a high diversity of STs, with the predominant types being ST-2353, ST-10, ST-48, ST-38, and ST-450. Our study is the first to report that ST-2353 is associated with multi-drug resistance genes in Ethiopia. Further research including other domains such water and food products are needed to comprehensively study this diversity and the spread of antimicrobial resistance genes to better understand their acquisition. We suggest implementing an integrated One Health surveillance system, which would be able to monitor transmission events and detect resistant bacteria in a timely manner from both humans and animals.

Abbreviations

AMR	Antimicrobial resistance
ESBL	Extended spectrum beta lactamase
<i>E. coli</i>	<i>Escherichia coli</i>
WGS	Whole genome sequencing
MLST	Multilocus sequence typing
SRS	Somali regional state

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13756-024-01502-5>.

Additional file1 (DOCX 456 KB)

Acknowledgements

We would like to thank pastoralist and agro-pastoralist communities, and the field team (Ahmed, Dek, Fuad, Mohammed, Mohammad, Ramadan, and Shamil). We would also like to thank the Jigjiga One Health Initiative team at Jigjiga University and the Armauer Hansen Research Institute in Ethiopia, as well as the Human and Animal Health Unit team at the Swiss Tropical and Public Health Institute in Switzerland, and the Microbiota-targeted Interventions Group at the University of Lausanne for helpful discussions and support. We would also like to thank Prof. Andrea Endimiani for his valuable suggestions and comments.

Author contributions

AM, RT, JZ, GC and PV developed the research questions. AM, AA, YO, and SH conducted laboratory work, supervised by EI and PV. SH and TS performed the bioinformatics analysis. JH contributed to data analysis. AM wrote the first draft of the manuscript and all authors (AA, SH, YO, RT, SY, TS, JH, JZ, GC, and PV) revised and approved the final text.

Funding

Open access funding provided by University of Lausanne. This work is funded by Jigjiga One Health Initiative (JOHI) (SDC) (no. 7F-09057.01.02 to JZ), Swiss Government Excellence Scholarships (ESKAS), Nutricia Research Foundation (no. 2019-20 to PV), Forschungsfonds of the University of Basel (Fellowship in 2020 to PV), Return Grant of the SNSF (no. P3P3PA_177877 to PV) and the Eccellenza Professorial Fellowship (no. PCEFP3_194545 to PV).

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Ethical approval was obtained from the Swiss Ethics Committee of Northwest and Central Switzerland (Ethikkommission Nordwest- und Zentralschweiz; REQ-2020-00608), the Review Committee of Armauer Hansen Research Institute in Addis Ababa, Ethiopia (AF-10-015), the Review Committee of the University of Jigjiga in Ethiopia (JJU-RERC030/2020), and National Research Ethics Review Committee (NRERC) (D2/152/533/4). A written consent was obtained from the parent or legal guardian of all participating children before study enrolment (signed or finger print). Data was recorded using the Open Data Kit and securely stored on a server at the Swiss TPH in Basel. All personally identifiable information was maintained by the local study team in Ethiopia and securely stored in a closed cupboard.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Swiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123 Allschwil, Switzerland. ²University of Basel, Petersplatz 1, 4003 Basel, Switzerland. ³Present Address: Department of Fundamental Microbiology, University of Lausanne, UNIL-Sorge, 1015 Lausanne, Switzerland. ⁴Jigjiga University, Jigjiga, Ethiopia. ⁵Armauer Hansen Research Institute, PO Box 1005, Addis Ababa, Ethiopia.

Received: 18 February 2024 Accepted: 28 November 2024

Published online: 18 December 2024

References

- Díaz-Agero Pérez C, et al. Local prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in *Klebsiella pneumoniae*: a prevalence survey in a Spanish University Hospital. *BMJ Open*. 2019;9(3):e024879. <https://doi.org/10.1136/bmjopen-2018-024879>.

2. Falgenhauer L, et al. Detection and characterization of ESBL-producing *Escherichia coli* from humans and poultry in Ghana. *Front Microbiol.* 2019;9:3358.
3. Ojo OE, Schwarz S, Michael GB. Detection and characterization of extended-spectrum β -lactamase-producing *Escherichia coli* from chicken production chains in Nigeria. *Vet Microbiol.* 2016;194:62–8.
4. Moremi N, et al. Faecal carriage of CTX-M extended-spectrum beta-lactamase-producing Enterobacteriaceae among street children dwelling in Mwanza city, Tanzania. *PLoS ONE.* 2017;12(9): e0184592. <https://doi.org/10.1371/journal.pone.0184592>.
5. Andriatahina T, et al. High prevalence of fecal carriage of extended-spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in a pediatric unit in Madagascar. *BMC Infect Dis.* 2010;10:1–8.
6. Ayinla AO, Mateus AL. Extended-spectrum beta-lactamases in poultry in Africa: a systematic review. *Front Antibiot.* 2023;2:1140750.
7. Rousham EK, Unicomb L, Islam MA. Human, animal and environmental contributors to antibiotic resistance in low-resource settings: integrating behavioural, epidemiological and One Health approaches. *Proc R Soc B Biol Sci.* 1876;2018(285):20180332.
8. Williams PC, Isaacs D, Berkley JA. Antimicrobial resistance among children in sub-Saharan Africa. *Lancet Infect Dis.* 2018;18(2):e33–44.
9. Bush K, Bradford PA. β -Lactams and β -lactamase inhibitors: an overview. *Cold Spring Harb Perspect Med.* 2016. <https://doi.org/10.1101/cshperspect.a025247>.
10. Cantón R, González-Alba JM, Galán JC. CTX-M enzymes: origin and diffusion. *Front Microbiol.* 2012;3:110. <https://doi.org/10.3389/fmicb.2012.00110>.
11. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. *Clin Microbiol Infect.* 2008;14(Suppl 1):159–65. <https://doi.org/10.1111/j.1469-0691.2007.01855.x>.
12. Hawser S, et al. Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. *Eur J Clin Microbiol Infect Dis.* 2011;30:173–9.
13. Wickramasinghe NH, et al. High community faecal carriage rates of CTX-M ESBL-producing *Escherichia coli* in a specific population group in Birmingham, UK. *J Antimicrob Chemother.* 2012;67(5):1108–13. <https://doi.org/10.1093/jac/dks018>.
14. Bonnet R. Growing group of extended-spectrum β -lactamases: the CTX-M enzymes. *Antimicrob Agents Chemother.* 2004;48(1):1–14.
15. Carattoli A, et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother.* 2014;58(7):3895–903.
16. Hirai I, et al. Detection of chromosomal blaCTX-M-15 in *Escherichia coli* O25b-B2-ST131 isolates from the Kinki region of Japan. *Int J Antimicrob Agents.* 2013;42(6):500–6.
17. Rodríguez I, et al. Chromosomal location of blaCTX-M genes in clinical isolates of *Escherichia coli* from Germany, The Netherlands and the UK. *Int J Antimicrob Agents.* 2014;43(6):553–7.
18. Leverstein-van Hall M, et al. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. *Clin Microbiol Infect.* 2011;17(6):873–80.
19. Liebana E, et al. Public health risks of enterobacterial isolates producing extended-spectrum β -lactamases or AmpC β -lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options. *Clin Infect Dis.* 2013;56(7):1030–7.
20. Sewunet T, et al. Polyclonal spread of blaCTX-M-15 through high-risk clones of *Escherichia coli* at a tertiary hospital in Ethiopia. *J Glob Antimicrob Resist.* 2022;29:405–12. <https://doi.org/10.1016/j.jgar.2021.09.017>.
21. Negeri AA, et al. Characterization of plasmids carrying bla CTX-M genes among extra-intestinal *Escherichia coli* clinical isolates in Ethiopia. *Sci Rep.* 2023;13(1):8595.
22. Negeri AA, et al. Antimicrobial resistance profiling and molecular epidemiological analysis of extended spectrum β -lactamases produced by extraintestinal invasive *Escherichia coli* isolates from Ethiopia: the presence of international high-risk clones ST131 and ST410 revealed. *Front Microbiol.* 2021;12: 706846.
23. Desta K, et al. High gastrointestinal colonization rate with extended-spectrum β -lactamase-producing Enterobacteriaceae in hospitalized patients: emergence of carbapenemase-producing *K. pneumoniae* in Ethiopia. *PLoS ONE.* 2016;11(8): e0161685.
24. Onis MD. The WHO child growth standards. *Pediatric nutrition in practice.* 2008; pp. 254–269.
25. Allen ME. MacConkey agar plates protocols. *American Society for Microbiology;* 2005. p. 1–4.
26. Performance C. Standards for antimicrobial susceptibility testing, CLSI supplement M100S. Wayne: Clinical and Laboratory Standards Institute; 2016.
27. Magiorakos A, et al. Bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Microbiology.* 2011;118(3):268–81.
28. Magiorakos A-P, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012;18(3):268–81.
29. Humphries RM, et al. CLSI methods development and standardization working group best practices for evaluation of antimicrobial susceptibility tests. *J Clin Microbiol.* 2018. <https://doi.org/10.1128/jcm.01934-17>.
30. Kit WHDE. Wizard[®] HMW DNA extraction kit. Available from: https://ch.promega.com/products/nucleic-acid-extraction/genomic-dna/high-molecular-weight-dna-extraction-kit/?gclid=CjwKCjw9pGjBhB-EiwAa5jl3GqNYZYh3g71uzXCHQOerfMShQDjueve5xxhApgcBryeACn9tY4YBoCZ_8QAvD_BwE&catNum=A2920.
31. Kolmogorov M, et al. Assembly of long, error-prone reads using repeat graphs. *Nat Biotechnol.* 2019;37(5):540–6.
32. Brettin T, et al. RASTtk: a modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. *Sci Rep.* 2015;5(1):8365.
33. Larsen MV, et al. Multilocus sequence typing of total-genome-sequenced bacteria. *J Clin Microbiol.* 2012;50(4):1355–61.
34. Alcock BP, et al. CARD 2023: expanded curation, support for machine learning, and resistome prediction at the comprehensive antibiotic resistance database. *Nucleic Acids Res.* 2022;51(D1):D690–9. <https://doi.org/10.1093/nar/gkac920>.
35. Katoh K, et al. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res.* 2002;30(14):3059–66.
36. Bortolaia V, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. *J Antimicrob Chemother.* 2020;75(12):3491–500. <https://doi.org/10.1093/jac/dkaa345>.
37. Epidemiology, C.f.G. Center for genomics epidemiology 2024 [cited 2024 16.06.2024]; Available from: <http://www.genomicsepidemiology.org/>.
38. R Core Team, R., R: A language and environment for statistical computing. 2013.
39. Bezabih YM, et al. The global prevalence and trend of human intestinal carriage of ESBL-producing *Escherichia coli* in the community. *J Antimicrob Chemother.* 2021;76(1):22–9. <https://doi.org/10.1093/jac/dkaa399>.
40. Bezabih YM, et al. Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing *Escherichia coli* between healthcare and community settings: a systematic review and meta-analysis. *JAC-Antimicrob Resist.* 2022. <https://doi.org/10.1093/jacamr/dlac048>.
41. Akenten CW, et al. Carriage of ESBL-producing *Klebsiella pneumoniae* and *Escherichia coli* among children in rural Ghana: a cross-sectional study. *Antimicrob Resist Infect Control.* 2023;12(1):60.
42. Ayukekbong JA, Ntemgwam M, Atabe AN. The threat of antimicrobial resistance in developing countries: causes and control strategies. *Antimicrob Resist Infect Control.* 2017;6(1):1–8.
43. Berendes D, et al. Human faeces-associated extended-spectrum β -lactamase-producing *Escherichia coli* discharge into sanitation systems in 2015 and 2030: a global and regional analysis. *Lancet Planet Health.* 2020;4(6):e246–55. [https://doi.org/10.1016/s2542-5196\(20\)30099-1](https://doi.org/10.1016/s2542-5196(20)30099-1).
44. Nüesch-Inderbilen M, et al. Antimicrobial resistant and extended-spectrum β -lactamase (ESBL) producing *Escherichia coli* isolated from fecal samples of African dromedary camels. *Sci Afr.* 2020;7: e00274.
45. Muhummed AM, et al. Knowledge, attitudes, and practices of rural communities regarding antimicrobial resistance and climate change in Adadle District, Somali Region, Ethiopia: a mixed-methods study. *Antibiotics.* 2024;13(4):292.
46. Alonso C, et al. Antibiotic resistance in *Escherichia coli* in husbandry animals: the African perspective. *Lett Appl Microbiol.* 2017;64(5):318–34.
47. Valentin L, et al. Subgrouping of ESBL-producing *Escherichia coli* from animal and human sources: an approach to quantify the distribution

- of ESBL types between different reservoirs. *Int J Med Microbiol*. 2014;304(7):805–16.
48. Day MJ, et al. Extended-spectrum β -lactamase-producing *Escherichia coli* in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. *Lancet Infect Dis*. 2019;19(12):1325–35.
 49. Aibinu I, et al. Sequence type ST131 and ST10 complex (ST617) predominant among CTX-M-15-producing *Escherichia coli* isolates from Nigeria. *Clin Microbiol Infect*. 2012;18(3):E49–51.
 50. Mshana SE, et al. Predictors of blaCTX-M-15 in varieties of *Escherichia coli* genotypes from humans in community settings in Mwanza, Tanzania. *BMC Infect Dis*. 2016;16:187. <https://doi.org/10.1186/s12879-016-1527-x>.
 51. Moremi N, et al. Predominance of CTX-M-15 among ESBL producers from environment and fish gut from the shores of Lake Victoria in Mwanza, Tanzania. *Front Microbiol*. 2016;7:1862.
 52. Joffré E, et al. Identification of new heat-stable (STa) enterotoxin allele variants produced by human enterotoxigenic *Escherichia coli* (ETEC). *Int J Med Microbiol*. 2016;306(7):586–94.
 53. Kwon T, et al. Comparative genomic analysis and characteristics of NCCP15740, the major type of enterotoxigenic *Escherichia coli* in Korea. *Gut Pathog*. 2017;9:1–7.
 54. Nicolas-Chanoine M-H, et al. Intercontinental emergence of *Escherichia coli* clone O25: H4-ST131 producing CTX-M-15. *J Antimicrob Chemother*. 2008;61(2):273–81.
 55. Pankok F, et al. Epidemiology of plasmids in *Escherichia coli* and *Klebsiella pneumoniae* with acquired extended spectrum beta-lactamase genes isolated from chronic wounds in Ghana. *Antibiotics*. 2022. <https://doi.org/10.3390/antibiotics11050689>.
 56. Minja CA, Shirima G, Mshana SE. Conjugative plasmids disseminating ctx-m-15 among human, animals and the environment in Mwanza Tanzania: a need to intensify one health approach. *Antibiotics*. 2021;10(7):836.
 57. Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M β -lactamases: temporal and geographical shifts in genotype. *J Antimicrob Chemother*. 2017;72(8):2145–55.
 58. Zankari E, et al. Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. *J Antimicrob Chemother*. 2013;68(4):771–7. <https://doi.org/10.1093/jac/dks496>.
 59. Moura A et al. Phenotypic and genotypic antimicrobial resistance of *Listeria monocytogenes*: an observational study in France. *Lancet Reg Health—Europe* 2024;37.
 60. Yee R, Dien Bard J, Simmer PJ. The genotype-to-phenotype dilemma: How should laboratories approach discordant susceptibility results? *J Clin Microbiol*. 2021. <https://doi.org/10.1128/jcm.00138-20>.
 61. Zhong Y, et al. Characterization of extended-spectrum beta-lactamase-producing *Escherichia coli* isolates from Jurong Lake, Singapore with whole-genome-sequencing. *Int J Environ Res Public Health*. 2021;18(3):937.
 62. Enne VI, et al. Evidence of antibiotic resistance gene silencing in *Escherichia coli*. *Antimicrob Agents Chemother*. 2006;50(9):3003–10.
 63. Tola MA, et al. High prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* fecal carriage among children under five years in Addis Ababa, Ethiopia. *PLoS ONE*. 2021;16(10):e0258117. <https://doi.org/10.1371/journal.pone.0258117>.
 64. Herindrainy P, et al. Rectal carriage of extended-spectrum beta-lactamase-producing gram-negative bacilli in community settings in Madagascar. *PLoS ONE*. 2011;6(7):e22738. <https://doi.org/10.1371/journal.pone.0022738>.
 65. Isendahl J, et al. Fecal carriage of ESBL-producing *E coli* and *K pneumoniae* in children in Guinea-Bissau: a hospital-based cross-sectional study. *PLoS ONE*. 2012;7(12):e51981. <https://doi.org/10.1371/journal.pone.0051981>.
 66. Tellevik MG, et al. High prevalence of faecal carriage of ESBL-producing enterobacteriaceae among children in Dar es Salaam, Tanzania. *PLoS ONE*. 2016;11(12):e0168024. <https://doi.org/10.1371/journal.pone.0168024>.
 67. Woerther P-L, et al. Massive increase, spread, and exchange of extended spectrum β -lactamase-encoding genes among intestinal Enterobacteriaceae in hospitalized children with severe acute malnutrition in Niger. *Clin Infect Dis*. 2011;53(7):677–85.
 68. De Lauzanne A, et al. Prevalence and factors associated with faecal carriage of extended-spectrum β -lactamase-producing Enterobacteriales among peripartum women in the community in Cambodia. *J Antimicrob Chemother*. 2022;77(10):2658–66.
 69. Rytter MJ, et al. The immune system in children with malnutrition—a systematic review. *PLoS ONE*. 2014;9(8):e105017. <https://doi.org/10.1371/journal.pone.0105017>.
 70. Cissé G. Food-borne and water-borne diseases under climate change in low- and middle-income countries: Further efforts needed for reducing environmental health exposure risks. *Acta Trop*. 2019;194:181–8. <https://doi.org/10.1016/j.actatropica.2019.03.012>.
 71. Magnano San Lio R, et al. How antimicrobial resistance is linked to climate change: an overview of two intertwined global challenges. *Int J Environ Res Public Health*. 2023;20(3):1681.
 72. Nielsen A-M, et al. Chlorination for low-cost household water disinfection—a critical review and status in three Latin American countries. *Int J Hyg Environ Health*. 2022;244: 114004.
 73. Montealegre MC, et al. Drinking water chlorination impact on fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bangladeshi children in a double-blind, cluster-randomized controlled trial. *Environ Health Perspect*. 2022;130(11): 117702.
 74. Krige M. Molecular investigation of the chlorine and antibiotic resistance mechanisms of *Escherichia coli* isolated from natural water sources in the Western Cape. Stellenbosch: University of Stellenbosch; 2009.
 75. Xiao X, et al. Chlorine tolerance and cross-resistance to antibiotics in poultry-associated salmonella isolates in China. *Front Microbiol*. 2021;12: 833743. <https://doi.org/10.3389/fmicb.2021.833743>.
 76. Jin M, et al. Chlorine disinfection promotes the exchange of antibiotic resistance genes across bacterial genera by natural transformation. *ISME J*. 2020;14(7):1847–56. <https://doi.org/10.1038/s41396-020-0656-9>.
 77. Aworh MK, et al. Extended-spectrum β -lactamase-producing *Escherichia coli* among humans, chickens and poultry environments in Abuja, Nigeria. *One Health Outlook*. 2020;2(1):8. <https://doi.org/10.1186/s42522-020-00014-7>.
 78. Langata LM, et al. Antimicrobial resistance genes in *Salmonella* and *Escherichia coli* isolates from chicken droppings in Nairobi, Kenya. *BMC Res Notes*. 2019;12(1):22. <https://doi.org/10.1186/s13104-019-4068-8>.
 79. Liaqat Z, et al. Isolation and molecular characterization of extended spectrum beta lactamase producing *Escherichia coli* from chicken meat in Pakistan. *PLoS ONE*. 2022;17(6):e0269194. <https://doi.org/10.1371/journal.pone.0269194>.
 80. Rahman MM, et al. Isolation and molecular characterization of multidrug-resistant *Escherichia coli* from chicken meat. *Sci Rep*. 2020;10(1):21999. <https://doi.org/10.1038/s41598-020-78367-2>.
 81. Badr H, et al. Multidrug-resistant and genetic characterization of extended-spectrum beta-lactamase-producing *E. coli* recovered from chickens and humans in Egypt. *Animals*. 2022;12(3):346.
 82. Overdeest I, et al. Extended-spectrum β -lactamase genes of *Escherichia coli* in chicken meat and humans, The Netherlands. *Emerg Infect Dis*. 2011;17(7):1216.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.